Coverage dated September 21, 2026 to September 22, 2026

StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day

Headline from Geneng News

Novo said it planned to launch “more than five multi-blockbusters” or drugs with multiple billions of dollars in sales every year through 2030, and generate more than DKK 150 billion (just over $23 billion) in risk-adjusted pipeline sales by 2035.

Geneng News's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

4 articles, oldest first.

Bloomberg
Novo Touts Future Blockbuster Launches, Disappointing Investors (opens Bloomberg)
Published Sep 21, 2026
Bloomberg's feed description
Novo Nordisk A/S plans to launch more than five blockbusters by the end of the decade as the Danish drugmaker tries to stay competitive in the increasingly crowded obesity market.
Quartz
Novo Nordisk stock sinks after 2030 growth plan fails to impress investors (opens Quartz)
Published Sep 21, 2026
Quartz's feed description
The Danish drugmaker pledged to launch 5 multi-blockbuster drugs by 2030 and grow revenue in line with peers, but investors wanted more
Geneng News
StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day (opens Geneng News)
Published Sep 21, 2026
Geneng News's feed description
Novo said it planned to launch “more than five multi-blockbusters” or drugs with multiple billions of dollars in sales every year through 2030, and generate more than DKK 150 billion (just over $23 billion) in risk-adjusted pipeline sales by 2035.
Bloomberg
Novo CEO Says Drugmaker Has More to Do to Win Over Investors (opens Bloomberg)
Published Sep 22, 2026
Bloomberg's feed description
Novo Nordisk A/S Chief Executive Officer Mike Doustdar said the company must do more to build investor confidence as the Ozempic maker faces a patent cliff for its biggest drugs at the beginning of the next decade.